Steady hands appear to be in control.
I'm amazed that NTII has held its gains even as the volume has dried up. A run up like this one is usually followed by profit taking especially after the volume declines. Also, the MMs tend to short a stock during a run up, then, when the dust settles, bring the price down and cover. But, this has not happened. This is all an excellent sign for the future movement of NTII.
BTW: I wouldn't expect much from Xerecept. I've basically written it off. There are far too few patients enrolled to make anything of the data. In addition, Xerecept is probably better suited for Juvenile brain tumor indications than for adults. The use of steroids is not a big problem in adults, so there is only a small advantage to Xerecept. In children, on the other hand, dosing with steroids is not a good idea. So, there is a clearer market here. If NTII pursues this at all it will only be with a partner. So, if something happens with Xerecept, consider it a bonus. But, don't base your valuation of NTII on it.
Have a great Thanksgiving y'awl.
John de C |
